Circulation. 2023 Nov 14;148(20):1636-1664. doi: 10.1161/CIR.0000000000001186. Epub 2023 Oct 9.
A growing appreciation of the pathophysiological interrelatedness of metabolic risk factors such as obesity and diabetes, chronic kidney disease, and cardiovascular disease has led to the conceptualization of cardiovascular-kidney-metabolic syndrome. The confluence of metabolic risk factors and chronic kidney disease within cardiovascular-kidney-metabolic syndrome is strongly linked to risk for adverse cardiovascular and kidney outcomes. In addition, there are unique management considerations for individuals with established cardiovascular disease and coexisting metabolic risk factors, chronic kidney disease, or both. An extensive body of literature supports our scientific understanding of, and approach to, prevention and management for individuals with cardiovascular-kidney-metabolic syndrome. However, there are critical gaps in knowledge related to cardiovascular-kidney-metabolic syndrome in terms of mechanisms of disease development, heterogeneity within clinical phenotypes, interplay between social determinants of health and biological risk factors, and accurate assessments of disease incidence in the context of competing risks. There are also key limitations in the data supporting the clinical care for cardiovascular-kidney-metabolic syndrome, particularly in terms of early-life prevention, screening for risk factors, interdisciplinary care models, optimal strategies for supporting lifestyle modification and weight loss, targeting of emerging cardioprotective and kidney-protective therapies, management of patients with both cardiovascular disease and chronic kidney disease, and the impact of systematically assessing and addressing social determinants of health. This scientific statement uses a crosswalk of major guidelines, in addition to a review of the scientific literature, to summarize the evidence and fundamental gaps related to the science, screening, prevention, and management of cardiovascular-kidney-metabolic syndrome.
对代谢风险因素(如肥胖和糖尿病、慢性肾脏病和心血管疾病)之间病理生理相互关系的认识不断提高,导致了心血管-肾脏-代谢综合征概念的提出。代谢危险因素和慢性肾脏病在心血管-肾脏-代谢综合征中的融合与不良心血管和肾脏结局的风险密切相关。此外,对于已经患有心血管疾病且同时存在代谢危险因素、慢性肾脏病或两者的个体,有独特的管理考虑因素。大量文献支持我们对心血管-肾脏-代谢综合征的科学理解,以及对该综合征患者的预防和管理方法。然而,在心血管-肾脏-代谢综合征方面,仍存在与疾病发展机制、临床表型内的异质性、健康社会决定因素和生物风险因素之间的相互作用、以及在竞争风险背景下准确评估疾病发生率等相关的关键知识空白。此外,支持心血管-肾脏-代谢综合征临床护理的数据也存在关键局限性,特别是在早期生活预防、危险因素筛查、跨学科护理模式、支持生活方式改变和减肥的最佳策略、针对新兴心脏保护和肾脏保护疗法的目标、同时患有心血管疾病和慢性肾脏病的患者的管理,以及系统评估和解决健康社会决定因素的影响。本科学声明使用了主要指南的交叉引用,以及对科学文献的回顾,以总结与心血管-肾脏-代谢综合征的科学、筛查、预防和管理相关的证据和基本差距。